BDTX241220P5000
- 2.50
- -0.15-5.66%
Black Diamond Therapeutics Newsroom
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $16
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $16
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)
Black Diamond Therapeutic Analyst Ratings
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $18
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Black Diamond Theraptcs Is Maintained at Overweight by Piper Sandler
Black Diamond Therapeutic Analyst Ratings
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12